The GSK3B inhibitor reduces the production of IL-6, TNFα, IL-17, and IL-1β in the BALF of mice with lipopolysaccharide-induced acute respiratory distress syndrome, thus relieving the lung injury [41]. Here, GSK3B is linked to acute respiratory distress syndrome.